scout
|Videos|February 7, 2023

Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME